Expert Interview
A second look: Discussing the Standard of Care for acromegaly patients and the potential of paltusotine, an oral SST2 agonist with a PDUFA date of September 25, 2025
Ticker(s): CRNXInstitution: Barrow Neurological Institute
- Neuroendocrinologist and Medical Director of the Barrow Pituitary Center and Neuroendocrinology Clinic.
- Currently manages ~50 patients with Cushing's Syndrome and has prescribed Recorlev to 6 of them.
- Clinical and research interests include the diagnosis and treatment of pituitary and adrenal tumors, pituitary dysfunction, growth hormone deficiency and excess, hypogonadism, and cortisol deficiency and excess.
How are they managed?
Added By: wilson_adminHow do you envision using paltusotine, assuming it gets approval?
Added By: wilson_adminHow many acromegaly patients do you treat
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
